Latest Breaking News On - Sangel capital - Page 6 : comparemela.com

SHENZHEN, China, Sept. 7, 2022 /PRNewswire/ Sangel Capital ("Sangel" or the "Company"), a leading biotech and healthcare venture capital company based in China, has announced that Liu Mulong, Founding Partner with the Company, has been awarded as one of China's top early-stage investors of 2021 by the acclaimed ChinaVenture Awards. The accolade recognizes the Company's position as a leader in the venture capital community, whose forward-looking investment strategy and expertise in life sciences set a strong foundation for a series of highly-promising fledgling healthcare projects to grow into ground-breaking solutions. "Our uniquely differentiated investment strategy has enabled us to find diamonds in the rough. We are one of a small number of local institutions in China with a solid track record of discovering and investing in early-stage bio-medicine, medical technology and medical device companies. The last 12 years have seen us investing in some of

United statesLiu mulongDuan jianxinSirnaomics ltdMagpie pharmaceuticalsAscentawits pharmaceuticalsSangel capitalFounding partnerYinyi biotechHuaheng biotech